metformin has been researched along with Cardiomegaly in 19 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study demonstrates that metformin is able to attenuate HHcy-induced cardiac hypertrophy by decreasing myocardial fibrosis and apoptosis." | 8.02 | Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy. ( Huang, J; Song, W; Wang, D; Xu, C; Zhao, Q, 2021) |
| "To identify the role of metformin in cardiac hypertrophy and investigate the possible mechanism underlying this effect." | 7.77 | Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. ( Fu, YN; Jiang, SY; Ma, XW; Xiao, H; Xu, M; Zhang, YY, 2011) |
| "This study demonstrates that metformin is able to attenuate HHcy-induced cardiac hypertrophy by decreasing myocardial fibrosis and apoptosis." | 4.02 | Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy. ( Huang, J; Song, W; Wang, D; Xu, C; Zhao, Q, 2021) |
| " However, the potential effects of metformin on cardiac hypertrophy are still unclear." | 4.02 | Metformin suppresses phenylephrine-induced hypertrophic responses by inhibiting p300-HAT activity in cardiomyocytes. ( Funamoto, M; Hasegawa, K; Katanasaka, Y; Katayama, A; Miyazaki, Y; Morimoto, T; Nurmila, S; Shimizu, K; Shimizu, S; Sunagawa, Y, 2021) |
| "Metformin is a popular antidiabetic agent that is also used to treat heart failure patients with type 2 diabetes mellitus." | 3.91 | Metformin Enhances Autophagy and Provides Cardioprotection in δ-Sarcoglycan Deficiency-Induced Dilated Cardiomyopathy. ( Kanamori, H; Kawaguchi, T; Kawasaki, M; Mikami, A; Minatoguchi, S; Naruse, G; Takemura, G; Watanabe, T; Yamada, Y; Yoshida, A, 2019) |
| " Accordingly, O304 reduced fasting plasma glucose levels and homeostasis model assessment of insulin resistance (HOMA-IR) in a proof-of-concept phase IIa clinical trial in type 2 diabetes (T2D) patients on Metformin." | 3.88 | PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. ( Backlund, F; Berggren, E; Bergqvist, I; Dahl, U; Edlund, H; Edlund, T; Ericsson, M; Eriksson, B; Kjellkvist, E; Lidh, E; Lindahl, E; Linde, K; Lundberg, I; Steneberg, P; Straseviciene, J; Westman, J, 2018) |
| "To identify the role of metformin in cardiac hypertrophy and investigate the possible mechanism underlying this effect." | 3.77 | Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. ( Fu, YN; Jiang, SY; Ma, XW; Xiao, H; Xu, M; Zhang, YY, 2011) |
| "Fibrosis is a general term encompassing a plethora of pathologies that span all systems and is marked by increased deposition of collagen." | 2.53 | AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. ( Beauloye, C; Bertrand, L; Daskalopoulos, EP; Dufeys, C; Horman, S, 2016) |
| "Senescence-associated pathological cardiac hypertrophy (SA-PCH) is associated with upregulation of foetal genes, fibrosis, senescence-associated secretory phenotype (SASP), cardiac dysfunction and increased morbidity and mortality." | 1.72 | Bmi-1-RING1B prevents GATA4-dependent senescence-associated pathological cardiac hypertrophy by promoting autophagic degradation of GATA4. ( Chen, H; Gu, X; Jin, J; Li, Q; Liang, J; Mao, Z; Miao, D; Wang, R; Xie, C; Zhang, Y; Zhou, J; Zuo, G, 2022) |
| "PTEN deletion-induced cardiac hypertrophy and contractile anomalies were associated with dampened phosphorylation of PTEN-inducible kinase 1 (Pink1) and AMPK." | 1.42 | Targeted deletion of PTEN in cardiomyocytes renders cardiac contractile dysfunction through interruption of Pink1-AMPK signaling and autophagy. ( Hu, N; Kandadi, MR; Pang, J; Ren, J; Roe, ND; Weiser-Evans, MC; Xu, X, 2015) |
| "AMP-kinase (AMPK) activation reduces cardiac hypertrophy, although underlying molecular mechanisms remain unclear." | 1.40 | Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. ( Barreto-Torres, G; Hernández, JS; Javadov, S; Khuchua, Z; Kuznetsov, AV, 2014) |
| "The roles of SHP in cardiac hypertrophy were tested in primary cultured cardiomyocytes and in animal models." | 1.40 | Small heterodimer partner blocks cardiac hypertrophy by interfering with GATA6 signaling. ( Ahn, Y; Cho, YK; Choe, N; Choi, HC; Choi, HS; Eom, GH; Joung, H; Kim, DK; Kim, HS; Kim, Y; Kim, YH; Kim, YS; Kook, H; Kwon, DH; Lee, CH; Lee, IK; Min, HK; Nam, KI; Nam, YS; Park, DH; Suk, K, 2014) |
| "Myocardial fibrosis is a key process in diabetic cardiomyopathy." | 1.39 | Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. ( Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 2 |
| Zhou, J | 1 |
| Liang, J | 1 |
| Xie, C | 1 |
| Gu, X | 1 |
| Wang, R | 1 |
| Mao, Z | 1 |
| Zhang, Y | 1 |
| Li, Q | 1 |
| Zuo, G | 1 |
| Miao, D | 1 |
| Jin, J | 1 |
| Zheng, D | 1 |
| Chen, L | 1 |
| Wei, Q | 1 |
| Zhu, Z | 1 |
| Liu, Z | 1 |
| Jin, L | 1 |
| Yang, G | 1 |
| Xie, X | 1 |
| Chakrabarti, M | 1 |
| Jain, N | 1 |
| Bhadra, MP | 1 |
| Zhao, Q | 1 |
| Song, W | 1 |
| Huang, J | 1 |
| Wang, D | 2 |
| Xu, C | 1 |
| Sunagawa, Y | 1 |
| Shimizu, K | 2 |
| Katayama, A | 1 |
| Funamoto, M | 1 |
| Nurmila, S | 1 |
| Shimizu, S | 1 |
| Miyazaki, Y | 1 |
| Katanasaka, Y | 1 |
| Hasegawa, K | 1 |
| Morimoto, T | 1 |
| Ghandi, Y | 1 |
| Habibi, D | 1 |
| Nasri, K | 1 |
| Alinejad, S | 1 |
| Taherahmad, H | 1 |
| Arjmand Shabestari, A | 1 |
| Nematinejad, A | 1 |
| Steneberg, P | 1 |
| Lindahl, E | 1 |
| Dahl, U | 1 |
| Lidh, E | 1 |
| Straseviciene, J | 1 |
| Backlund, F | 1 |
| Kjellkvist, E | 1 |
| Berggren, E | 1 |
| Lundberg, I | 1 |
| Bergqvist, I | 1 |
| Ericsson, M | 1 |
| Eriksson, B | 1 |
| Linde, K | 1 |
| Westman, J | 1 |
| Edlund, T | 1 |
| Edlund, H | 1 |
| Kanamori, H | 1 |
| Naruse, G | 1 |
| Yoshida, A | 1 |
| Minatoguchi, S | 2 |
| Watanabe, T | 1 |
| Kawaguchi, T | 1 |
| Yamada, Y | 1 |
| Mikami, A | 1 |
| Kawasaki, M | 1 |
| Takemura, G | 1 |
| Wang, B | 1 |
| Shen, D | 1 |
| Tang, J | 1 |
| Li, J | 1 |
| Xiao, Y | 1 |
| Chen, X | 1 |
| Cao, C | 1 |
| Han, D | 1 |
| Gao, E | 1 |
| Zhao, W | 1 |
| Zhang, J | 1 |
| Chang, J | 1 |
| Picatoste, B | 1 |
| Ramírez, E | 1 |
| Caro-Vadillo, A | 1 |
| Iborra, C | 1 |
| Ares-Carrasco, S | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, O | 1 |
| Hernández, JS | 1 |
| Barreto-Torres, G | 1 |
| Kuznetsov, AV | 1 |
| Khuchua, Z | 1 |
| Javadov, S | 1 |
| Nam, YS | 1 |
| Kim, Y | 1 |
| Joung, H | 1 |
| Kwon, DH | 1 |
| Choe, N | 1 |
| Min, HK | 1 |
| Kim, YS | 1 |
| Kim, HS | 1 |
| Kim, DK | 1 |
| Cho, YK | 1 |
| Kim, YH | 1 |
| Nam, KI | 1 |
| Choi, HC | 1 |
| Park, DH | 1 |
| Suk, K | 1 |
| Lee, IK | 1 |
| Ahn, Y | 1 |
| Lee, CH | 1 |
| Choi, HS | 1 |
| Eom, GH | 1 |
| Kook, H | 1 |
| Roe, ND | 1 |
| Xu, X | 1 |
| Kandadi, MR | 1 |
| Hu, N | 1 |
| Pang, J | 1 |
| Weiser-Evans, MC | 1 |
| Ren, J | 1 |
| Daskalopoulos, EP | 1 |
| Dufeys, C | 1 |
| Bertrand, L | 1 |
| Beauloye, C | 1 |
| Horman, S | 1 |
| Mummidi, S | 1 |
| Das, NA | 1 |
| Carpenter, AJ | 1 |
| Kandikattu, H | 1 |
| Krenz, M | 1 |
| Siebenlist, U | 1 |
| Valente, AJ | 1 |
| Chandrasekar, B | 1 |
| Li, T | 1 |
| Jiang, S | 1 |
| Yang, Z | 1 |
| Ma, Z | 1 |
| Yi, W | 1 |
| Yang, Y | 1 |
| Lee, HH | 1 |
| Yeh, CH | 1 |
| Chen, YT | 1 |
| Chi, TC | 1 |
| Cheng, JT | 1 |
| Lo, SH | 1 |
| Fu, YN | 1 |
| Xiao, H | 1 |
| Ma, XW | 1 |
| Jiang, SY | 1 |
| Xu, M | 1 |
| Zhang, YY | 1 |
| Ashour, AE | 1 |
| Sayed-Ahmed, MM | 1 |
| Abd-Allah, AR | 1 |
| Korashy, HM | 1 |
| Maayah, ZH | 1 |
| Alkhalidi, H | 1 |
| Mubarak, M | 1 |
| Alhaider, A | 1 |
2 reviews available for metformin and Cardiomegaly
| Article | Year |
|---|---|
AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation.
Topics: Aging; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Berberine; Cardiomegaly; Extracell | 2016 |
Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?
Topics: Adolescent; AMP-Activated Protein Kinases; Animals; Cardiomegaly; Cardiomyopathies; Child, Preschool | 2017 |
17 other studies available for metformin and Cardiomegaly
| Article | Year |
|---|---|
Bmi-1-RING1B prevents GATA4-dependent senescence-associated pathological cardiac hypertrophy by promoting autophagic degradation of GATA4.
Topics: Animals; Atrial Natriuretic Factor; Autophagy; Cardiomegaly; Cytomegalovirus Infections; GATA4 Trans | 2022 |
[Fucoxanthin regulates Nrf2/Keap1 signaling to alleviate myocardial hypertrophy in diabetic rats].
Topics: Animals; Antioxidants; Atrial Natriuretic Factor; Cardiomegaly; Diabetes Mellitus, Experimental; Fib | 2022 |
Metformin induces a shift from glycolysis to fatty acid oxidation in cardiac hypertrophy via PHB1.
Topics: Cardiomegaly; Fatty Acids; Glycolysis; Humans; Metformin | 2023 |
Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy.
Topics: Adult; Animals; Apoptosis; Cardiomegaly; Cells, Cultured; Fibrosis; Heart; Humans; Hyperhomocysteine | 2021 |
Metformin suppresses phenylephrine-induced hypertrophic responses by inhibiting p300-HAT activity in cardiomyocytes.
Topics: Acetylation; Adrenergic alpha-1 Receptor Agonists; Animals; Cardiomegaly; Cells, Cultured; E1A-Assoc | 2021 |
Effect of well-controlled gestational diabetes on left ventricular diastolic dysfunction in neonates.
Topics: Adult; Cardiomegaly; Case-Control Studies; Cross-Sectional Studies; Diabetes, Gestational; Echocardi | 2019 |
PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiovascular | 2018 |
Metformin Enhances Autophagy and Provides Cardioprotection in δ-Sarcoglycan Deficiency-Induced Dilated Cardiomyopathy.
Topics: Animals; Autophagy; Cardiomegaly; Cardiomyopathies; Cardiomyopathy, Dilated; Diabetes Mellitus, Type | 2019 |
Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate ameliorates pressure overload-induced cardiac hypertrophy and dysfunction through inhibiting autophagy.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Autophagy; Cardiomegaly; Cell Line; Heart Fa | 2019 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Di | 2013 |
Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Car | 2014 |
Small heterodimer partner blocks cardiac hypertrophy by interfering with GATA6 signaling.
Topics: Animals; Atrial Natriuretic Factor; Binding Sites; Cardiomegaly; Disease Models, Animal; GATA6 Trans | 2014 |
Targeted deletion of PTEN in cardiomyocytes renders cardiac contractile dysfunction through interruption of Pink1-AMPK signaling and autophagy.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Autophagy; Cardiomegaly; Enzyme Acti | 2015 |
Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; AMP-Activated Protein Kinases; Animals; Cardiomeg | 2016 |
Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.
Topics: Animals; Body Weight; Cardiomegaly; Drug Therapy, Combination; Eating; Male; Metformin; Mice; Mice, | 2010 |
Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Cardiomegaly; Echocardiography; Enzyme Activation; Heart; Hy | 2011 |
Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats.
Topics: Animals; Cardiomegaly; Coenzyme A; Doxorubicin; Energy Metabolism; Gene Expression Regulation; Gluta | 2012 |